J Korean Med Assoc.  2013 Apr;56(4):321-325. 10.5124/jkma.2013.56.4.321.

Clinical use of oral contraceptives

• Lee DY
• Choi D

• KMID: 2192934
• DOI: http://doi.org/10.5124/jkma.2013.56.4.321

Abstract

Since oral contraceptives (OCs) were first introduced in 1960, they have been used as a highly effective contraceptive method for over 50 years. Besides the prevention of pregnancy, they provide various non-contraceptive benefits. Well-known non-contraceptive benefits related to menstruation include reduction of dysmenorrhea and heavy menstrual bleeding. In addition, many women see improvements in acne and symptoms from premenstrual syndrome/premenstrual dysphoric disorder with OC use. In addition, OCs also can be used for the management of endometriosis or polycystic ovarian syndrome, and have also been reported to decrease the risk of ovarian and endometrial cancer. Consequently, many women may choose to use OCs in light of their non-contraceptive benefits. These non-contraceptive benefits can encourage women to select OCs as an useful option for contraception, improving their quality of life, and even providing public health benefits. Therefore, clinicians should be familiar with OCs and able to provide detailed information regarding their non-contraceptive benefits. The purpose of this article is to review the current evidence for the non-contraceptive benefits of OCs.

Keyword

Oral contraceptives; Non-contraceptive benefits

MeSH Terms

Acne Vulgaris
Contraception
Contraceptives, Oral
Dysmenorrhea
Endometrial Neoplasms
Endometriosis
Female
Hemorrhage
Humans
Light
Menstruation
Polycystic Ovary Syndrome
Pregnancy
Public Health
Quality of Life
Contraceptives, Oral

Reference

1. Hauksson A, Akerlund M, Melin P. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist. Br J Obstet Gynaecol. 1988. 95:898–904.

2. Pulkkinen MO. Prostaglandins and the non-pregnant uterus: the pathophysiology of primary dysmenorrhea. Acta Obstet Gynecol Scand Suppl. 1983. 113:63–67.

3. Lundstrom V, Green K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978. 130:640–646.

4. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004. 69:469–476.

5. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991. 31:66–70.

6. Maia H Jr, Casoy J, Correia T, Freitas L, Pimentel K, Athayde C, Coutinho E. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol. 2006. 22:547–551.

7. Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 1999. 60:255–262.

8. Cassidenti DL, Paulson RJ, Serafini P, Stanczyk FZ, Lobo RA. Effects of sex steroids on skin 5 alpha-reductase activity in vitro. Obstet Gynecol. 1991. 78:103–107.

9. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012. 7:CD004425.

10. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, Zhang P, Patel H, Foegh M. PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001. 10:561–569.

11. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005. 106:492–501.

12. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007. 335:651.

13. Moore J, Kennedy S, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2000. (2):CD001019.

14. Lee DY, Bae DS, Yoon BK, Choi D. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010. 25:3050–3054.

15. Seracchioli R, Mabrouk M, Frasca C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010. 94:464–471.

16. Olive DL. Medical therapy of endometriosis. Semin Reprod Med. 2003. 21:209–222.

17. Maia H Jr, Casoy J, Correia T, Freitas LA, Pimentel K, Athayde C. The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis. Gynecol Endocrinol. 2008. 24:123–128.

18. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Fedele L. 'Blood On The Tracks' from corpora lutea to endometriomas. BJOG. 2009. 116:366–371.

19. Vercellini P, DE Matteis S, Somigliana E, Buggio L, Frattaruolo MP, Fedele L. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic re-view and meta-analysis. Acta Obstet Gynecol Scand. 2013. 92:8–16.

20. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome. Contraception. 2010. 82:139–146.

21. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006. 85:436–440.

22. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, Boivin J, Petraglia F, Wijeyeratne CN, Norman RJ, Dunaif A, Franks S, Wild RA, Dumesic D, Barnhart K. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012. 97:28–38.e25.

23. Tarlatzis BC, Grimbizis G, Bontis J, Mantalenakis S. Ovarian stimulation and ovarian tumours: a critical reappraisal. Hum Reprod Update. 1995. 1:284–301.

24. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use. N Engl J Med. 1987. 316:650–655.

25. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 1995. 85(5 Pt 1):793–801.

26. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008. 371:303–314.

27. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA. Hereditary Ovarian Cancer Clinical Study Group. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007. 8:26–34.

28. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010. 340:c927.

29. Grimbizis GF, Tarlatzis BC. The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2010. 24:29–38.

30. Lee DY, Koo YA, Yoon BK, Choi D. Reproductive health characteristics of urban South Korean women. Gynecol Obstet Invest. 2010. 70:154–159.